Z-LEHD-FMK
CAT:
804-HY-P1010-02
Size:
1 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Z-LEHD-FMK
- CAS Number: 210345-04-3
- UNSPSC Description: Z-LEHD-FMK is a selective and irreversible inhibitor of caspase-9, protects against lethal reperfusion injury and attenuates apoptosis. Z-LEHD-FMK exhibits the neuroprotective effect in a rat model of spinal cord trauma[1][2][3].
- Target Antigen: Apoptosis; Caspase
- Type: Peptides
- Related Pathways: Apoptosis
- Applications: Cancer-programmed cell death
- Field of Research: Cancer; Neurological Disease
- Assay Protocol: https://www.medchemexpress.com/z-lehd-fmk.html
- Purity: 98.09
- Solubility: DMSO : 100 mg/mL (ultrasonic;warming)
- Smiles: O=C(N[C@@H](CC(C)C)C(N[C@@H](CCC(OC)=O)C(N[C@@H](CC1=CN=CN1)C(N[C@@H](CC(OC)=O)C(CF)=O)=O)=O)=O)OCC2=CC=CC=C2
- Molecular Weight: 690.72
- References & Citations: [1]Ozoren N, et, al. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2000 Nov 15; 60(22): 6259-65.|[2]Colak A, et, al. Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury. J Neurosurg Spine. 2005 Mar; 2(3): 327-34.|[3]Mocanu MM, et, al. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 2000 May; 130(2): 197-200.Food Chem Toxicol. 2018 Oct;120:143-154.|Food Chem Toxicol. 2019 Oct;132:110655. |Food Chem Toxicol. 2020 Dec;146:111843.|J Cell Mol Med. 2019 Apr;23(4):2489-2504.|J Cell Mol Med. 2020 Jul;24(14):8151-8165.|Oxid Med Cell Longev. 26 Jun 2022.|Sci Adv. 2023 Oct 6;9(40):eadi6586.|mSphere. 2024 May 17:e0023624.|Preprints. 2024 Aug 14.|Virol Sin. 2024 May 30:S1995-820X(24)00078-6.
- Shipping Conditions: Blue Ice
- Storage Conditions: -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
- Clinical Information: No Development Reported